why choose us

First received: August 15, 2024

Clinical Trial: BARDA BP-I-23-001 H5 Influenza

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Influenza

Study Type: INTERVENTIONAL


Official Title: Randomized, Double-Blind, Phase 2 Study to Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03® or MF59®

Brief Summary: This BARDA-sponsored, randomized, double-blind, phase 2 study is designed to assess safety and immunogenicity of A/H5 inactivated monovalent influenza vaccines at different antigen dose levels adjuvanted with AS03 or MF59.

Read more